Clinical bottom line
Chronic pelvic venous insufficiency (CPVI) is an under-recognized contributor to chronic pelvic pain and venous disorders in women, characterized by venous reflux and obstruction in the pelvic veins. Recent advances emphasize improved diagnostic imaging and minimally invasive endovascular therapies, such as embolization and stenting, which show promise in symptom relief and quality-of-life improvement. However, evidence remains limited by heterogeneous patient populations and variable diagnostic criteria, warranting cautious interpretation. Clinicians should consider CPVI in differential diagnosis of chronic pelvic pain and collaborate with interventional specialists to optimize individualized management.
What the evidence shows
CPVI arises from venous reflux or obstruction affecting pelvic veins, including ovarian and internal iliac veins, leading to venous hypertension and pelvic congestion syndrome (PCS). Clinical manifestations often include chronic pelvic pain, dyspareunia, and lower extremity varicosities (Dewald et al., 2024). Diagnosis relies on a combination of clinical assessment and imaging modalities such as duplex ultrasound, magnetic resonance venography, and catheter-based venography, which remain the gold standard for confirming venous reflux and obstruction (Dewald et al., 2024; Ezekwueme et al., 2026).
Interventional therapies have evolved substantially. Endovascular embolization of incompetent ovarian and pelvic veins is increasingly utilized, demonstrating symptomatic improvement in selected patients with PCS (Dewald et al., 2024). In cases complicated by venous obstruction, such as May-Thurner syndrome, endovascular stenting has shown efficacy in restoring venous outflow and alleviating symptoms (Ezekwueme et al., 2026). These minimally invasive approaches offer advantages over traditional surgical ligation, including reduced morbidity and shorter recovery times.
Pharmacologic and conservative measures, including compression therapy and analgesics, remain adjunctive but are often insufficient as monotherapy for CPVI-related symptoms (Dewald et al., 2024). The pathophysiology of CPVI overlaps with other causes of chronic pelvic pain, complicating diagnosis and treatment selection (Chronic Pelvic Pain in Women, 2025). Multidisciplinary evaluation is therefore critical.
Caveats and uncertainty
Despite advances, the evidence base for CPVI management is limited by small, heterogeneous cohorts and lack of randomized controlled trials. Diagnostic criteria for CPVI and PCS vary across studies, and imaging findings do not always correlate with symptom severity (Dewald et al., 2024). Long-term outcomes of embolization and stenting remain incompletely characterized, with some reports noting symptom recurrence or need for reintervention (Ezekwueme et al., 2026).
Furthermore, CPVI often coexists with other pelvic pathologies, such as endometriosis or musculoskeletal disorders, complicating attribution of symptoms solely to venous insufficiency (Chronic Pelvic Pain in Women, 2025). The potential for overtreatment exists if CPVI is diagnosed based on imaging alone without clear clinical correlation.
Pharmacologic options lack robust evidence for efficacy in CPVI, and conservative measures provide limited relief. The role of novel therapies and optimal patient selection criteria require further elucidation.
How this may change practice
Increased awareness of CPVI as a cause of chronic pelvic pain may prompt earlier consideration of venous imaging in appropriate patients, particularly those with refractory symptoms and clinical signs of pelvic venous congestion. Collaboration with vascular and interventional radiology specialists is essential to tailor diagnostic evaluation and therapeutic interventions.
Endovascular embolization and stenting represent promising minimally invasive options that may reduce symptom burden and improve quality of life, potentially shifting management away from more invasive surgical approaches. However, clinicians should counsel patients regarding the current limitations of evidence, including variable response rates and need for long-term follow-up.
Integrating CPVI assessment into multidisciplinary chronic pelvic pain programs may enhance diagnostic accuracy and optimize individualized treatment plans. Future research should focus on standardized diagnostic criteria, randomized trials of interventional therapies, and long-term outcomes to refine clinical guidelines.